(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Investigate Business Mastercard Choices for Better Rewards and Rewards - 2IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
- 3Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- 4The Beginning Of The End For Fossil Fuels Can Start In Colombia
- 5The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- Artemis II astronauts arrive in Florida to prepare for launch to the moon
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
- Figure out How to Establish a long term connection with Your Handshake
- Pleasant Cycle Courses All over the Planet
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Figure out How to Augment Your Rooftop Substitution Speculation
